About this Journal Submit a Manuscript Table of Contents
Journal of Thyroid Research
Volume 2012 (2012), Article ID 847108, 10 pages
http://dx.doi.org/10.1155/2012/847108
Review Article

Thyroid Cancer: Molecular Aspects and New Therapeutic Strategies

1Department of Medical Oncology, Ramón y Cajal University Hospital, 28034 Madrid, Spain
2Department of Endocrinology, Ramón y Cajal University Hospital, 28034 Madrid, Spain
3Department of Endocrinology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain
4Department of Medical Oncology, Vall d’Hebron University Hospital, 08035 Barcelona, Spain

Received 1 March 2012; Accepted 13 May 2012

Academic Editor: Fausto Bogazzi

Copyright © 2012 Enrique Grande et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Asioli, L. A. Erickson, A. Righi et al., “Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression,” Modern Pathology, vol. 23, no. 9, pp. 1269–1278, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Y. Chen, A. Jemal, and E. M. Ward, “Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005,” Cancer, vol. 115, no. 16, pp. 3801–3807, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. L. Enewold, K. Zhu, E. Ron et al., “Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 3, pp. 784–791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Shimaoka, D. A. Schoenfeld, and W. D. DeWys, “A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma,” Cancer, vol. 56, no. 9, pp. 2155–2160, 1985. View at Scopus
  5. T. Kondo, S. Ezzat, and S. L. Asa, “Pathogenetic mechanisms in thyroid follicular-cell neoplasia,” Nature Reviews Cancer, vol. 6, no. 4, pp. 292–306, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Sipos and M. H. Shah, “Thyroid cancer: emerging role for targeted therapies,” Therapeutic Advances in Medical Oncology, vol. 2, no. 1, pp. 3–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Y. Soh, M. S. Eigelberger, K. J. Kim et al., “Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo,” Surgery, vol. 128, no. 6, pp. 1059–1066, 2000. View at Scopus
  8. X. M. Yu, C. Y. Lo, W. F. Chan, K. Y. Lam, P. Leung, and J. M. Luk, “Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases,” Clinical Cancer Research, vol. 11, no. 22, pp. 8063–8069, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. S. Haq, R. V. McCready, and C. L. Harmer, “Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy,” Nuclear Medicine Communications, vol. 25, no. 8, pp. 799–805, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Schlumberge and S. Sherman, “Approach to the patient with advanced differentiated thyroid cancer,” European Journal of Endocrinology, vol. 166, no. 1, pp. 5–11, 2011.
  11. A. Matuszczyk, S. Petersenn, A. Bockisch et al., “Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium,” Hormone and Metabolic Research, vol. 40, no. 3, pp. 210–213, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Licitra, L. D. Locati, A. Greco, R. Granata, and P. Bossi, “Multikinase inhibitors in thyroid cancer,” European Journal of Cancer, vol. 46, no. 6, pp. 1012–1018, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. E. C. L. De Souza, A. C. Ferreira, and D. P. De Carvalho, “The mTOR protein as a target in thyroid cancer,” Expert Opinion on Therapeutic Targets, vol. 15, no. 9, pp. 1099–1112, 2011. View at Publisher · View at Google Scholar
  14. V. Marotta, A. Guerra, M. R. Sapio, and M. Vitale, “RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint,” European Journal of Endocrinology, vol. 165, no. 4, pp. 499–507, 2011. View at Publisher · View at Google Scholar
  15. A. Bounacer, M. Schlumberger, R. Wicker et al., “Search for NTRK1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation,” British Journal of Cancer, vol. 82, no. 2, pp. 308–314, 2000. View at Scopus
  16. V. Gupta-Abramson, A. B. Troxel, A. Nellore et al., “Phase II trial of sorafenib in advanced thyroid cancer,” Journal of Clinical Oncology, vol. 26, no. 29, pp. 4714–4719, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. R. T. Kloos, M. D. Ringel, M. V. Knopp et al., “Phase II trial of sorafenib in metastatic thyroid cancer,” Journal of Clinical Oncology, vol. 27, no. 10, pp. 1675–1684, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Ahmed, Y. Barbachano, A. Riddell et al., “Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population,” European Journal of Endocrinology, vol. 165, no. 2, pp. 315–322, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Hoftijzer, K. A. Heemstra, H. Morreau et al., “Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma,” European Journal of Endocrinology, vol. 161, no. 6, pp. 923–931, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Capdevila, L. Iglesias, I. Halperin et al., “Sorafenib in metastatic thyroid cancer,” Endocrine-Related Cancer, vol. 19, no. 2, pp. 209–216, 2012. View at Publisher · View at Google Scholar
  21. S. Leboulleux, L. Bastholt, T. M. Krause, et al., “Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular; DTC): a randomized, double-blind phase II trial,” in Proceedings of the 4th International Thyroid Congress, Abstract OC-023, Paris, France, 2010.
  22. E. E. W. Cohen, L. S. Rosen, E. E. Vokes et al., “Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study,” Journal of Clinical Oncology, vol. 26, no. 29, pp. 4708–4713, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. L. L. Carr, D. A. Mankoff, B. H. Goulart et al., “Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation,” Clinical Cancer Research, vol. 16, no. 21, pp. 5260–5268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. E. E. Cohen, B. M. Needles, K. J. Cullen, et al., “Phase 2 study of sunitinib in refractory thyroid cancer,” Journal of Clinical Oncology, vol. 26, supplement, abstract 6025, 2008.
  25. S. I. Sherman, B. Jarzab, M. E. Cabanillas, et al., “A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC),” Journal of Clinical Oncology, vol. 29, supplement, abstract 5503, 2011.
  26. S. I. Sherman, L. J. Wirth, J. P. Droz et al., “Motesanib diphosphate in progressive differentiated thyroid cancer,” New England Journal of Medicine, vol. 359, no. 1, pp. 31–42, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. K. C. Bible, V. J. Suman, J. R. Molina et al., “Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study,” The Lancet Oncology, vol. 11, no. 10, pp. 962–972, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. A. Wells Jr., B. G. Robinson, R. F. Gagel et al., “Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial,” Journal of Clinical Oncology, vol. 30, no. 2, pp. 134–141, 2012. View at Publisher · View at Google Scholar
  29. R. Kurzrock, S. I. Sherman, D. W. Ball et al., “Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer,” Journal of Clinical Oncology, vol. 29, no. 19, pp. 2660–2666, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. E. T. Lam, M. D. Ringel, R. T. Kloos et al., “Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer,” Journal of Clinical Oncology, vol. 28, no. 14, pp. 2323–2330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. M. J. Schlumberger, R. Elisei, L. Bastholt et al., “Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer,” Journal of Clinical Oncology, vol. 27, no. 23, pp. 3794–3801, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. J. A. De Souza, N. Busaidy, A. Zimrin, et al., “Phase II trial of sunitinib in medullary thyroid cancer (MTC),” Journal of Clinical Oncology, vol. 28, supplement, abstract 5504, no. 15s, 2010.
  33. L. Santarpia, J. N. Myers, S. I. Sherman, F. Trimarchi, G. L. Clayman, and A. K. El-Naggar, “Genetic alterations in the Ras/Raf/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma,” Cancer, vol. 116, no. 12, pp. 2974–2983, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. E. Grande-Pulido, B. Castelo, and P. J. Fonseca, “Efficacy and tolerability of sunitinib in patients with advanced thyroid cancer out of a trial: a Spanish multicenter cohort,” Journal of Clinical Oncology, vol. 29, supplement, abstract e16024, 2011.
  35. M. Cakir and A. B. Grossman, “Medullary thyroid cancer: molecular biology and novel molecular therapies,” Neuroendocrinology, vol. 90, no. 4, pp. 323–348, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. F. Pacini, M. G. Castagna, C. Cipri, and M. Schlumberger, “Medullary thyroid carcinoma,” Clinical Oncology, vol. 22, no. 6, pp. 475–485, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. J. E. Phay and M. H. Shah, “Targeting RET receptor tyrosine kinase activation in cancer,” Clinical Cancer Research, vol. 16, no. 24, pp. 5936–5941, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. F. Perri, G. D. Lorenzo, G. D. Scarpati, and C. Buonerba C, “Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options,” World Journal of Clinical Oncology, vol. 2, no. 3, pp. 150–157, 2011.
  39. G. Nagaiah, P. Fu, J. K. Wasman, et al., “CTRU Research Nurses. Phase II trial of sorafenib (bay 43-9006) in patients with advanced anaplastic carcinoma of the thyroid,” Journal of Clinical Oncology, vol. 27, supplement, abstract 6058, no. 15s, 2009.
  40. J. A. Sosa, R. Elisei, B. Jarzab, et al., “A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): final survival analysis for the FACT trial,” Journal of Clinical Oncology, vol. 29, supplement, abstract 5502, 2011.